Cleevewood Pharma Ltd

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—5

Registered number: 15821290

		31 July 2025
	Notes	£	£
FIXED ASSETS
Intangible Assets	4		785,379
Investments	5		1,100,621

			1,886,000
CURRENT ASSETS
Debtors	6	17,358
Cash at bank and in hand		469

		17,827
Creditors: Amounts Falling Due Within One Year	7	(617,360 )

NET CURRENT ASSETS (LIABILITIES)			(599,533 )

TOTAL ASSETS LESS CURRENT LIABILITIES			1,286,467

Creditors: Amounts Falling Due After More Than One Year	8		(1,288,407 )

NET LIABILITIES			(1,940 )

CAPITAL AND RESERVES
Called up share capital	9		1
Profit and Loss Account			(1,941 )

SHAREHOLDERS' FUNDS			(1,940)

Page 1

Page 2

Cleevewood Pharma Ltd

Balance Sheet (continued)

As At 31 July 2025

For the period ending 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Mr Sach Sembhi

Director

05/05/2026

The notes on pages 3 to 5 form part of these financial statements.

1. General Information

Cleevewood Pharma Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 15821290 . The registered office is Office 1 , 21 Hatherton Street, Walsall, West Midlands, England, WS4 2LA.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Going Concern Disclosure

The directors have not identified any material uncertainties related to events or conditions that may cast significant doubt about the company's ability to continue as a going concern.

2.3. Intangible Fixed Assets and Amortisation - Goodwill

Goodwill is the difference between amounts paid on the acquisition of a business and the fair value of the separable net assets. It is amortised to the profit and loss account over its estimated economic life of .... years.

3. Average Number of Employees

Average number of employees, including directors, during the period was: 6

4. Intangible Assets

	Goodwill
	£
Cost
As at 5 July 2024	-
Additions	785,379

As at 31 July 2025	785,379

Net Book Value
As at 31 July 2025	785,379

As at 5 July 2024	-

Page 3

Page 4

Cleevewood Pharma Ltd

Notes to the Financial Statements (continued)

For the Period 5 July 2024 to 31 July 2025

5. Investments

	Unlisted
	£
Cost or Valuation
As at 5 July 2024	-
Additions	1,100,621

As at 31 July 2025	1,100,621

Provision
As at 5 July 2024	-

As at 31 July 2025	-

Net Book Value
As at 31 July 2025	1,100,621

As at 5 July 2024	-

6. Debtors

	31 July 2025
	£
Due within one year
Other debtors	14,000
VAT	3,358

	17,358

7. Creditors: Amounts Falling Due Within One Year

	31 July 2025
	£
Bank loans and overdrafts	156,163
Other creditors	452,047
Accruals and deferred income	1,250
Directors' loan accounts	7,900

	617,360

8. Creditors: Amounts Falling Due After More Than One Year

	31 July 2025
	£
Bank loans	1,288,407

Page 4

Page 5

Cleevewood Pharma Ltd

Notes to the Financial Statements (continued)

For the Period 5 July 2024 to 31 July 2025

9. Share Capital

	31 July 2025
Allotted, called up and fully paid	£
100 Ordinary Shares of £ 0.01 each	1